Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.
|Videos|August 4, 2016
Dr. Garon on Immunotherapy for Patients With NSCLC
Author(s)Edward B. Garon, MD
Edward B Garon, MD, director, Thoracic Oncology, Jonnson Comprehensive Cancer Center, UCLA, discusses the evolution of immunotherapy for the treatment of patients with non–small cell lung cancer.
Advertisement
Edward B Garon, MD, director, Thoracic Oncology, Jonnson Comprehensive Cancer Center, UCLA, discusses the evolution of immunotherapy for the treatment of patients with non—small cell lung cancer (NSCLC).
The addition of immunotherapy agents to the treatment landscape of NSCLC has led to a very exciting time for a disease originally not believed to be immunogenic, Garon explains.
Today, evidence suggests that such agents could become the frontline choice for select patients with stage IV disease versus standard chemotherapy.
<<<
Advertisement
Related to this article
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
The opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.
Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.
Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.
Patients with resected RCC given adjuvant durvalumab with or without tremelimumab described persistent low-grade toxicities as most disruptive to QOL.
Experts in gynecologic oncology overview top research being presented at the 2026 ESMO Congress.
First-line IO-based combination regimens were increasingly used and associated with longer observed survival in advanced renal cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
2
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
3
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
4
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
5